1-3 of 3
Ram Kumar Singh, PhD
Close
Sort by
Journal Articles

The Anti-B-Cell Maturation Antigen (BCMA) Antibody-α-Amanitin Conjugate Hdp-101 Induces Immunogenic Cell Death and Immunologic Memory in Models of Multiple Myeloma

Ram Kumar Singh, PhD, Richard J. Jones, PhD, Fazal M. Shirazi, PhD, Jianxuan M. Zou, PhD, Hua Wang, PhD, Hans C. Lee, MD, Elisabet E. Manasanch, MD, Isere Kuiatse, PhD, Andreas Pahl, PhD, Robert Z. Orlowski, MDPhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 9–10.
https://doi.org/10.1182/blood-2020-141615
Published: 2020
Journal Articles

Activating KRAS , NRAS , and BRAF Mutants Enhance Proteasome Capacity and Reduce Endoplasmic Reticulum Stress in Multiple Myeloma, Thereby Promoting Plasma Cell Survival and Proteasome Inhibitor Resistance

Fazal Shirazi, PhD, Richard J. Jones, PhD, Isere Kuiatse, PhD, Zuzana Berkova, PhD, Hua Wang, PhD, Hans C. Lee, MD, Samuel Hong, PhD, Ram Kumar Singh, PhD, Lawrence Robert Dick, PhD, Nibedita Chattopadhyay, PhD, Robert Z. Orlowski, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 406.
https://doi.org/10.1182/blood-2018-99-117577
Published: 2018
Journal Articles

HDP101, a Novel B-Cell Maturation Antigen (BCMA)-Targeted Antibody Conjugated to α-Amanitin, Is Active Against Myeloma with Preferential Efficacy Against Pre-Clinical Models of Deletion 17p

Ram Kumar Singh, PhD, Richard J. Jones, PhD, Samuel Hong, PhD, Fazal Shirazi, PhD, Hua Wang, PhD, Isere Kuiatse, PhD, Andreas Pahl, Robert Z. Orlowski, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 593.
https://doi.org/10.1182/blood-2018-99-118412
Published: 2018